FDA grants Cinainu Breakthrough Therapy status for pediatric AA

Children with alopecia areata (AA) have no FDA-approved treatment, but an investigational topical botanical drug is moving closer to filling that gap. The FDA has granted Breakthrough Therapy designation to Cinainu (LH-8), a cutaneous solution from Legacy Healthcare, for moderate-to-severe AA in adults, adolescents, and children aged 2 years and older, the company announced October 13, 2026.¹

The designation is supported by the phase 2/3 RAAINBOW trial, in which Cinainu improved scalp hair regrowth vs placebo in children and adolescents, with benefits that persisted after treatment ended.¹˒²

"The FDA's decision represents a major milestone for Cinainu and recognizes its potential to address significant unmet needs in alopecia areata," said Saad Harti, chief executive officer of Legacy Healthcare.¹

Breakthrough Therapy designation is intended to expedite the development and review of investigational therapies with preliminary evidence of substantial improvement over available treatments.¹

RAAINBOW trial design and Cinainu efficacy in pediatric alopecia areata

RAAINBOW was an international, double-blind, placebo-controlled study that randomly assigned 107 patients aged 2 to 17 years 2:1 to Cinainu or placebo for 24 weeks, followed by a 24-week untreated follow-up period.² Eligible patients had active AA involving 25% to 95% of the scalp, with a disease duration of 6 months to 3 years.³ The primary analysis included 62 patients who met predefined criteria for moderate-to-severe disease.²

For the primary endpoint, relative change in Severity of Alopecia Tool (SALT) score from baseline to week 24, Cinainu outperformed placebo by an adjusted mean difference of 26.3% (95% CI, 0.1%-52.5%; P = .049; Cohen d = 0.52).² More Cinainu-treated patients achieved at least a 40% improvement in SALT score (26.2% vs 5.0%; P = .048).²

The between-group difference grew during the untreated follow-up, reaching 39.4% at week 48 (95% CI, 13.1%-65.6%; P = .003; Cohen d = 0.80).² Quality of life also improved, with effect sizes of 0.61 on the Children's Dermatology Life Quality Index and 0.69 on the EuroQol Visual Analogue Scale at week 24.² No serious adverse events were related to Cinainu, and treatment was well tolerated.²

Treatment gaps in moderate and pediatric alopecia areata

AA is an autoimmune, nonscarring hair loss disorder that significantly impairs quality of life and affects an estimated 6.8 million people in the US.²˒⁴ Oral Janus kinase (JAK) inhibitors are the only approved therapies, including baricitinib for adults with severe AA and ritlecitinib for patients aged 12 years and older.⁴ These agents are limited to severe disease, carry boxed warnings for serious infections, malignancy, cardiovascular events, and thrombosis, and hair loss can return rapidly after discontinuation.¹ Patients with moderate AA and younger children have no approved options.¹˒²

Cinainu mechanism and botanical drug development

Cinainu is a topical solution containing 4 botanical extracts with proposed anti-inflammatory, antiapoptotic, and antioxidant properties; investigators note that chemokines such as interleukin 8 and JAK-dependent signaling contribute to AA pathogenesis.² According to Legacy Healthcare, it is the first FDA-regulated multiplant botanical drug to receive Breakthrough Therapy designation.¹ The company suggests it could serve as a first-line option for moderate-to-severe AA and, pending further study, as continuation therapy after oral JAK inhibitors.¹

Interpreting RAAINBOW data and next steps for Cinainu

The RAAINBOW findings suggest a topical option with minimal systemic exposure could address a population that JAK inhibitors do not reach, but the evidence is early. The primary endpoint narrowly reached statistical significance, with a CI lower bound near zero, in a primary analysis of 62 patients.² Although the responder rate exceeded placebo, roughly 3 in 4 treated patients did not achieve a 40% SALT improvement.²

The designation also covers adults, although the supporting randomized data come from a pediatric trial.¹˒² Legacy Healthcare is preparing a global pivotal phase 3 program evaluating Cinainu in adults, adolescents, and children with moderate-to-severe AA.¹ Breakthrough Therapy designation does not constitute approval, and Cinainu remains investigational.

References

1. Legacy Healthcare's CINAINU receives FDA Breakthrough Therapy designation for alopecia areata in adults, adolescents and children aged 2 years and older. News release. Legacy Healthcare. October 13, 2026. Accessed October 15, 2026. https://www.prnewswire.com/news-releases/legacy-healthcares-cinainu-receives-fda-breakthrough-therapy-designation-for-alopecia-areata-in-adults-adolescents-and-children-aged-2-years-and-older-302906680.html

2. Blume-Peytavi U, Piraccini BM, Reygagne P, et al. Efficacy and safety of Cinainu in paediatric alopecia areata: an international, double-blind, randomized, placebo-controlled, phase II/III trial. Br J Dermatol. 2026;194(1):37-46. doi:10.1093/bjd/ljaf279

3. Efficacy and safety of LH-8 in paediatric alopecia areata. ClinicalTrials.gov identifier: NCT03240627. Updated December 9, 2023. Accessed October 15, 2026. https://clinicaltrials.gov/study/NCT03240627

4. FDA approves ritlecitinib for ages 12 and up for alopecia areata. MDedge. Published June 2023. Accessed October 15, 2026. https://mdedge.com/content/fda-approves-ritlecitinib-ages-12-and-alopecia-areata